Coverage
Filings
| Filing | Date |
|---|---|
| Directorate Change | 21 Feb 2025 |
| Nucala COPD submission accepted in China | 20 Feb 2025 |
| GSK 5-in-1 meningitis vaccine approved by US FDA | 17 Feb 2025 |
| Director/PDMR Shareholding | 13 Feb 2025 |
| Director/PDMR Shareholding | 11 Feb 2025 |
| Final Results | 5 Feb 2025 |
| Total Voting Rights | 3 Feb 2025 |
| EMA accepts two submissions for depemokimab | 28 Jan 2025 |
| Depemokimab dual filing in China and Japan |
GSK said Monday it has appointed Chief Commercial Officer Luke Miels as its next chief executive, succeeding Dame Emma Walmsley.
GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
GSK said on Monday that the U.S. Food and Drug Administration has accepted for review its application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to at-risk adults aged 18 to 49.
| 28 Jan 2025 |
| EMA accept review Shingrix syringe presentation | 27 Jan 2025 |
| Jemperli expanded approval in the EU | 20 Jan 2025 |
| Director/PDMR Shareholding | 16 Jan 2025 |